聯化科技(002250.SZ):目前公司合作的醫藥客戶均爲世界醫藥行業內優秀的大型公司
格隆匯3月12日丨聯化科技(002250.SZ)於近期投資者關係活動表示,公司醫藥業務按計劃逐步推進,預計醫藥業務將保持穩定發展。公司執行“大客戶戰略”,目前公司合作的醫藥客戶均爲世界醫藥行業內優秀的大型公司,公司在加深原有的大客戶合作的基礎上,繼續努力做好拓展新客戶、提高研發能力、加強技術儲備等工作。在產能建設方面,公司根據實際情況做好投資建設工作,計劃投建新的醫藥車間,以滿足未來醫藥業務發展的需要。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.